Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
|Videos|February 7, 2022
2021 Sigourney Award Winner: Supporting the Mission
Author(s)Jane G. Tillman, PhD, ABPP
This Sigourney Award winner is glad the recognition can continue supporting the mission of their work.
Advertisement
"This recognition from the Sigourney Trust is particularly important to us, as it supports our mission. It supports our efforts to think psychoanalytically about complex problems in the world, and it helps us hold a conversation with a broad range of constituents worldwide about the ideas that matter to them and the ways of understanding suffering in the world."
To read Dr Tillman's article, please see
Dr Tillman is the director of the Erikson Institute for Education, Research, and Advocacy at the Austen Riggs Center in Stockbridge, Massachusetts.
Advertisement
Related to this article
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5